Company / Cash & Equivalents
Bio-Techne Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$162.2M
FY2025
5-year range
$151.8M / $199.1M
FY2021-FY2025
Trend
+6.8%
vs FY2024
Sector context
#91 of 148
Health Care
What the data says
At $162M, Bio-Techne's cash & equivalents ranks #91 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $64M in FY2016 to $199M in FY2021.
Based on SEC 10-K filings.
$162M in FY2025 with a 5-year CAGR of +2.0%.
Declined from $181M to $162M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- +2.0%
- 10-Year CAGR
- -
Sector benchmark
#91 of 148 in Health CareTop 61% of 148This company $162.2M Sector average $1.2B
▼
-86.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 6.8% year-over-year.
- Ranks #91 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $162.2M | +6.8% |
| FY2024 | $151.8M | -15.9% |
| FY2023 | $180.6M | +4.6% |
| FY2022 | $172.6M | -13.3% |
| FY2021 | $199.1M | +35.8% |
| FY2020 | $146.6M | +45.3% |
| FY2019 | $100.9M | -17.3% |
| FY2018 | $122.0M | +33.2% |
| FY2017 | $91.6M | +42.6% |
| FY2016 | $64.2M | +17.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026